High risk — avoid this combination unless there is no good alternative.
Profound drowsiness, slowed or shallow breathing, dizziness, confusion, and increased risk of falls. The combination has caused serious, sometimes life-threatening respiratory depression — particularly in older adults, those with reduced lung function, and people also taking opioids. The FDA issued a Drug Safety Communication in December 2019 requiring updated Warnings/Precautions language on gabapentinoid labels for this risk.
Why this happens (mechanism)
Both drugs depress the central nervous system through different routes — alprazolam (Xanax) enhances GABA-A receptor activity, gabapentin modulates calcium channels and increases overall GABAergic tone. Stacked, the depressant effects on breathing, alertness, and coordination add up.
What to monitor
- Sedation level — can the patient be roused easily?
- Respiratory rate (especially overnight)
- Coordination and fall risk; consider home safety review in older adults
- Avoid driving or operating machinery until effect is known
Dose adjustment
Use the lowest effective dose of EACH drug; if both must be continued, start one at a clearly subtherapeutic dose and titrate while monitoring. Avoid concurrent opioids entirely.
Safer alternatives to consider
Avoids the additive CNS depressant load.
Either drug alone carries far less respiratory risk.
Always discuss alternatives with your prescriber before making any change. The right choice depends on your other medications, conditions, and what is working for you today.